Elsevier Launches Solution to Accelerate Drug Discovery Through Comprehensive Prediction and Assessment of Drug-drug Interactions

Monday, June 19, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 19, 2017 /PRNewswire/ --

New PharmaPendium solution comes

with DDI risk calculator enabling earlier and more complete risk mitigation strategies for potential drug-drug interactions

Elsevier, the information analytics company specializing in science

and health, has launched the PharmaPendium DMPK (Drug Metabolism-Pharmacokinetic) solution. The DMPK solution delivers searchable pharmacokinetic, metabolizing enzymes and transporters data to provide a complete picture of potential drug-drug interactions (DDIs) and drug candidate risk assessment.

PharmaPendium DMPK informs preclinical and clinical risk/benefit analyses - enabling researchers to make quick evaluations of which drug candidates to progress. The DMPK solution also includes a drug-drug interaction risk calculator (DDIRC), which is compliant with 2012 FDA guidelines on Industry Drug Interaction Studies. Together, the solutions support informed and accelerated decision-making.

In drug discovery and development, early and ongoing assessment of DDIs is critical. Undetected DDIs can lead to severe side effects, resulting in the refusal of regulatory approval, severe prescribing restrictions or the withdrawal of drugs from the market. The FDA reports that between 1995 and 2010, the proportion of adults dispensed five or more drugs doubled to 20.8%; the proportion dispensed ten or more tripled to 5.8%. DDIs account for between 3-5% of all reported adverse drug events and, with an aging population and this increasing trend towards polypharmacy, are an urgent concern.

PharmaPendium's DMPK Solution provides a unique source of searchable pharmacokinetic, metabolizing enzyme and transporter data and, together with DDIRC, allows users to predict potential interactions between an investigational drug and multiple drugs simultaneously - providing a full risk profile against marketed drugs.

"PharmaPendium's DMPK and DDIRC tools have had a significant impact on our drug development decisions," commented a senior DMPK scientist from a top pharma company that beta-tested the solution. "The solution delivers a level of information we can't get elsewhere, so we can get a full, detailed picture of risk assessment classified by therapeutic class. Without the DDI risk calculator, we would only focus on key drugs. But with DDIRC, within 30 minutes to half a day, we can analyze over 200 drugs - so it really saves us considerable time."

"For all scientists and researchers, patient safety is the paramount concern. Currently, identifying and assessing potential DDIs is an essential but resource-intensive task," said Guenther Kurapkat, Senior Vice President of Life Science Solutions, Elsevier. "The DMPK solution and DDI risk calculator save both time and cost. Not only by allowing comprehensive and simultaneous analyses of drug candidates, but also delivering more relevant information to the hands of scientists. This allows them to quickly and confidently prioritize the safest, most promising candidates for further development - and also supports more intelligent, and safer clinical trial design."

The DMPK solution contains over 2.2M pages of FDA approval documents, 680K pages of FDA Advisory Committee documents, and 200K pages of EMA approval documents. Over 4,400 drugs are indexed and fully searchable; with 1.6M extracted pharmacokinetic data lines and over 302K metabolizing enzyme and transporter lines. It delivers the information that scientists need to answer critical questions during drug development; including what other studies were conducted to assess DDI risks and what concerns regulatory agencies have previously expressed about potential DDIs.

The PharmaPendium DMPK Solution and DDIRC are available from June 19, 2017. For more information, please visit https://www.elsevier.com/solutions/pharmapendium.

About Elsevier 

Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles, and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contact Christopher Capot Global Communications, Elsevier +1-917-704-5174 [email protected]

SOURCE Elsevier



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store